SEARCH

SEARCH BY CITATION

References

  • Anderson , G. L. , H. L. Judd , A. M. Kaunitz , D. H. Barad , S. A. Beresford , M. Pettinger , J. Liu , S. G. McNeely & A. M. Lopez : Effect of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. J. Amer. Med. Ass. 2003, 290, 17391748.
  • Bernstein , L. & B. E. Henderson : Hormone intake: Relationship to cancer risk. In : Cancer prevention. Eds.: V. T.DeVita , S.Hellman and S. A.Rosenberg . JB Lippincott, Philadelphia, 1990, pp. 117.
  • Brinton , L. A. , R. N. Hoover & the Endometrial Cancer Collaborative Group: Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet. Gynecol. 1993, 81, 265271.
  • Casagrande , J. T. , E. W. Louie , M. C. Pike , S. Roy , R. K. Ross & B. E. Henderson : “Incessant ovulation” and ovarian cancer. Lancet 1979, 2, 170173.
  • Centers for Disease Control Cancer and Steroid Hormone Study: Oral contraceptive use and the risk of endometrial cancer. J. Amer. Med. Ass. 1983a, 249, 16001604.
  • Centers for Disease Control Cancer and Steroid Hormone Study: Oral contraceptive use and the risk of ovarian cancer. J. Amer. Med. Ass. 1983b, 249, 15961599.
  • Centers for Disease Control Cancer and Steroid Hormone Study: Combination oral contraceptive use and the risk of endometrial cancer. J. Amer. Med. Ass. 1987, 257, 796800.
  • Chlebowski , R. T. , S. L. Hendrix , R. D. Langer , M. L. Stefanick , M. Gass , D. Lane , R. J. Rodabough , M. A. Giilligan , M. T. Cyr , C. A. Thomson , J. Khandekar , H. Petrovitch & A. McTiernan : Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. J. Amer. Med. Ass. 2003, 289, 32433253.
  • Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996, 147, 17131727.
  • Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997, 350, 10471059.
  • Coughlin , S. S. , A. G. Giustozzi , S. J. Smith & N. C. Lee : A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. J. Clin. Epidemiol. 2000, 53, 367375.
  • Glud , E. , S. K. Kjær , B. L. Thomsen , C. Hogdall , L. Christensen , E. Hogdall , J. E. Bock & J. Blaakaer : Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. Arch. Intern. Med. 2004, 164, 22532259.
  • Goldin , C. & L. F. Katz : The power of the pill: oral contraceptives and women's career and marriage decisions. J. Political Economy 2002, 110, 730770.
  • Grady , D. & V. L. Ernster : Endometrial cancer. In : Cancer epidemiology and prevention. Eds.: D.Schottenfeld and J. F.Fraumeni , Jr. . Oxford University Press, New York, 1996, pp. 10581089.
  • Grady , D. , T. Gebretsadik , K. Kerlikowski , V. Ernster & D. Petitti : Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet. Gynecol. 1995, 85, 304313.
  • Greer , J. B. , M. Modugno , G. O. Allen & R. B. Ness : Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet. Gynecol. 2005, 105, 731740.
  • Hankinson , S. E. , G. A. Colditz , D. J. Hunter , T. L. Spencer , B. Rosner & M. J. Stampfer : A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet. Gynecol. 1992, 80, 708714.
  • Hemminki , E. , D. L. Kennedy , C. Baum & S. M. McKinlay : Prescribing non-contraceptive estrogens and progestogens in the United States, 1974–1986. Amer. J. Public Health 1988, 78, 14791481.
  • Henderson , B. E. , J. T. Casagrande , M. C. Pike , T. Mack , I. Rosario & A. Duke : The epidemiology of endometrial cancer in young women. Brit. J. Cancer 1983, 47, 749756.
  • Hulka , B. S. , L. E. Chambless , D. G. Kaufman , W. C. Fowler & B. G. Greenberg : Protection against endometrial carcinoma by combination-product oral contraceptives. J. Amer. Med. Ass. 1982, 247, 475477.
  • IMS, America: National Prescription Audit. IMS America, Ambler, PA, 1987.
  • Kaufman , D. G. , S. Shapiro , D. Slone , L. Rosenbert , O. S. Miettinen , P. D. Stolley , R. C. Knapp , T. Leavitt , W. G. Watring , N. B. Rosenshein , J. L. Lewlis , D. Schottenfeld & R. L. Engle : Decreased risk of endometrial cancer among oral-contraceptive users. New Engl. J. Med. 1980, 303, 10451047.
  • Kelsey , J. L. , V. A. LiVolsi , T. R. Holford , D. B. Fischer , E. D. Mostow , P. E. Schwartz , T. O'Connor & C. White : A case-control study of cancer of the endometrium. Amer. J. Epidemiol. 1982, 116, 333342.
  • Key , T. J. & M. C. Pike : The dose-effect relationship between “unopposed” oestrogen and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Brit. J. Cancer 1988, 57, 205212.
  • Kumle , M. , E. Weiderpass , T. Braaten , I. Persson , H. O. Adami & E. Lund : Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol. Biomarkers Prev. 2002, 11, 13741381.
  • Lacey , J. V. , Jr , P. J. Mink , J. H. Lubin , M. E. Sherman , R. Triosi , P. Hartge , A. Schatzkin & C. Schairer : Menopausal hormone replacement therapy and risk of ovarian cancer. J. Amer. Med. Ass. 2002, 288, 334341.
  • Lee , S. A. , R. K. Ross & M. C. Pike : An overview of menopausal estrogen-progestin hormone therapy and breast cancerrisk. Brit. J. Cancer 2005, 92, 20492058.
  • Magnusson , C. , J. A. Baron , N. Correia , R. Bergstrom , H. O. Adami & I. Persson : Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int. J. Cancer 1999, 81, 339344.
  • Marchbanks , P. A. , J. A. McDonald , H. G. Wilson , S. G. Folger , M. G. Mandel , J. R. Daling , L. Bernstein , K. E. Malone , G. Ursin , B. L. Strom , S. A. Norman , P. A. Wingo , R. T. Burkman , J. A. Berlin , M. S. Simon , R. Spirtas & L. K. Weiss : Oral contraceptives and the risk of breast cancer. New Engl. J. Med. 2002, 346, 20252032.
  • Million Women Study Collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003, 362, 419427.
  • Million Women Study Collaborators: Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005, 365, 15431551.
  • Ness , R. B. , J. A. Grisso , J. Klapper , J. J. Schlesselman , S. Silberzweig , R. Vergona , M. Morgan & J. E. Wheeler : and the Share Study Group. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Amer. J. Epidemiol. 2000, 152, 233241.
  • Newcomb , P. A. & A. Trentham-Dietz : Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control 2003, 14, 195201.
  • Pike , M. C. , L. Bernstein & D. V. Spicer : The relationship of exogenous hormones to breast cancer risk. In : Current therapy in oncology. Ed.: J. E.Niederhuber . Mosby, St. Louis, MO, 1993, pp. 292303.
  • Pike , M. C. , B. E. Henderson , M. D. Krailo , A. Duke & S. Roy : Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 1983, 2, 926930.
  • Pike , M. C. , C. L. Pearce , R. Peters , W. Cozen , P. Wan & A. H. Wu : Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. Fertil. Steril. 2004a, 82, 186195.
  • Pike , M. C. , C. L. Pearce & A. H. Wu : Prevention of cancers of the breast, endometrium and ovary. Oncogene 2004b, 23, 63796391.
  • Piper , J. M. & D. L. Kennedy : Oral contraceptives in the United States: trends in content and potency. Int. J. Epidemiol. 1987, 16, 215221.
  • Riman , T. , P. W. Dickman , S. Nilsson , N. Correia , H. Nordlinder , C. M. Magnusson & I. R. Persson : Risk factors for invasive epithelial ovarian cancer: Results from a Swedish case-control study. Amer. J. Epidemiol. 2002, 156, 363373.
  • Rodriguez , C. , A. V. Patel , E. E. Calle , E. J. Jacob & M. J. Thun : Estrogen replacement therapy and ovarian cancer mortality in a large prospective study of US women. J. Amer. Med. Ass. 2001, 285, 14601465.
  • Rodriguez , G. C. , D. K. Walmer , M. Cline , H. Krigman , B. A. Lessey , R. S. Whitaker , R. Dodge & C. L. Hughes : Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J. Soc. Gynecol. Invest. 1998, 5, 271276.
  • Rosenblatt , K. A. & D. B. Thomas & the WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial cancer. Int. J. Cancer 1991, 49, 870874.
  • Ross , R. K. , A. Paganini-Hill , P. C. Wan & M. C. Pike : Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl. Cancer Inst. 2000, 92, 328332.
  • Schairer , C. , J. H. Lubin , R. Triosi , S. Sturgeon , L. A. Brinton & R. Hoover : Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J. Amer. Med. Ass. 2000, 283, 485491.
  • Schildkraut , J. M. , B. Calingaert , P. A. Marchbanks , P. G. Moorman & G. C. Rodriguez : Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J. Natl. Cancer Inst. 2002, 94, 3238.
  • Schlesselman , J. : Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum. Reprod. 1997, 12, 18511863.
  • Sit , A. S. Y. , F. Modugno , J. L. Weissfeld , S. L. Berga & R. B. Ness : Hormone replacement therapy formulations and risk of epithelial ovarian carcinoma. Gynecol. Oncol. 2002, 86, 118123.
  • Stadel , B. V. : The etiology and prevention of ovarian cancer. Amer. J. Obstet. Gynecol. 1975, 123, 772774.
  • Stadel , B. V. , G. L. Rubin , L. A. Webster , J. J. Schlesselman & P. A. Wingo : Oral contraceptives and breast cancer in young women. Lancet 1985, 2, 970973.
  • Stanford , J. L. , L. A. Brinton , M. L. Berman , R. Mortel , L. B. Twiggs , R. J. Barrett , G. D. Wilbanks & R. N. Hoover : Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int. J. Cancer 1993, 54, 243248.
  • The Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. J. Amer. Med. Ass. 2004, 291, 17011712.
  • UK National Case-Control Study Group: Oral contraceptive use and breast cancer risk in young women. Lancet 1989, 1, 973982.
  • Voigt , L. F. , Q. Deng & N. S. Weiss : Recency, duration and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes Control 1994, 5, 227233.
  • Weiss , N. S. & T. A. Sayvetz : Incidence of endometrial cancer in relation to the use of oral contraceptives. New Engl. J. Med. 1980, 302, 551554.
  • Whittemore , A. S. , R. Harris & J. Itnyre : Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. Invasive epithelial ovarian cancers in white women. Collaborative Ovarian Cancer Group. Amer. J. Epidemiol. 1992, 136, 11841203.
  • WHO Collaborative Study of Neoplasia and Steroid Contraceptives: Endometrial cancer and combined oral contraceptives. Int. J. Epidemiol. 1988, 17, 263269.
  • Zeleniuch-Jacquotte , A. , A. Akhmedkhanov , I. Kato , K. L. Koenig , R. E. Shore , M. Y. Kim , M. Levitz , K. R. Mittal , U. Raju , S. Banerjee & P. Toniolo : Postmenopausal endogenous oestrogens and risk of endometrial cancer: results from a prospective study. Brit. J. Cancer 2001, 84, 975981.